Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 27 results.
User Information
Export Records
  1. 1.   Chemical Modulation of Pre-mRNA Splicing in Mammalian Systems
  2. Boer, Robert E.; Torrey, Zachary R.; Schneekloth,Jay
  3. ACS CHEMICAL BIOLOGY. 2020, Apr 17; 15(4): 808-818.
  1. 2.   Investigation of Unanticipated Alkylation at the N(pi) Position of a Histidyl Residue Under Mitsunobu Conditions and Synthesis of Orthogonally Protected Histidine Analogues
  2. Qian, W. J.; Liu, F.; Burke, T. R.
  3. Journal of Organic Chemistry. 2011, Nov; 76(21): 8885-8890.
  1. 3.   Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel
  2. Liu, F.; Park, J. E.; Qian, W. J.; Lim, D.; Graber, M.; Berg, T.; Yaffe, M. B.; Lee, K. S.; Burke, T. R.
  3. Nature Chemical Biology. 2011, Sep; 7(9): 595-601.
  1. 4.   A Dual-Readout F(2) Assay That Combines Fluorescence Resonance Energy Transfer and Fluorescence Polarization for Monitoring Bimolecular Interactions
  2. Du, Y. H.; Nikolovska-Coleska, Z.; Qui, M.; Li, L.; Lewis, I.; Dingledine, R.; Stuckey, J. A.; Krajewski, K.; Roller, P. P.; Wang, S. M.; Fu, H. A.
  3. Assay and Drug Development Technologies. 2011, Aug; 9(4): 382-393.
  1. 5.   Synthesis, Activity, and Structural Analysis of Novel alpha-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H
  2. Chung, S. M.; Himmel, D. M.; Jiang, J. K.; Wojtak, K.; Bauman, J. D.; Rausch, J. W.; Wilson, J. A.; Beutler, J. A.; Thomas, C. J.; Arnold, E.; Le Grice, S. F. J.
  3. Journal of Medicinal Chemistry. 2011, Jul; 54(13): 4462-4473.
  1. 6.   Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay
  2. Best, A. M.; Chang, J. J.; Dull, A. B.; Beutler, J. A.; Martinez, E. D.
  3. Journal of Biomedicine and Biotechnology. 2011 11.
  1. 7.   Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A
  2. Zuniga, J. E.; Hammill, J. T.; Drory, O.; Nuss, J. E.; Burnett, J. C.; Gussio, R.; Wipf, P.; Bavari, S.; Brunger, A. T.
  3. Plos One. 2010, Jun; 5(6): 15.
  1. 8.   12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers
  2. Rishi, V.; Oh, W. J.; Heyerdahl, S. L.; Zhao, J. F.; Scudiero, D.; Shoemaker, R. H.; Vinson, C.
  3. Journal of Structural Biology. 2010, May; 170(2): 216-225.
  1. 9.   Directed Discovery of Agents Targeting the Met Tyrosine Kinase Domain by Virtual Screening
  2. Peach, M. L.; Tan, N.; Choyke, S. J.; Giubellino, A.; Athauda, G.; Burke, T. R.; Nicklaus, M. C.; Bottaro, D. P.
  3. Journal of Medicinal Chemistry. 2009 52(4): 943-951.
  1. 10.   SYNTHESIS AND BIOLOGICAL EVALUATION OF INHIBITORS OF BOTULINUM NEUROTOXIN METALLOPROTEASE
  2. Wang, C. B.; Widom, J.; Petronijevic, F.; Burnett, J. C.; Nuss, J. E.; Bavari, S.; Gussio, R.; Wipf, P.
  3. Heterocycles. 2009 79: 487-520.
  1. 11.   Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53
  2. Clement, J. A.; Kitagaki, J.; Yang, Y.; Saucedo, C. J.; O'Keefe, B. R.; Weissman, A. M.; Mckee, T. C.; McMahon, J. B.
  3. Bioorganic & Medicinal Chemistry. 2008 16(23): 10022-10028.
  1. 12.   Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids
  2. Seiple, L. A.; Cardellina, J. H.; Akee, R.; Stivers, J. T.
  3. Molecular Pharmacology. 2008 73(3): 669-677.
  1. 13.   A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype a metalloprotease
  2. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Solaja, B. A.; Bavari, S.
  3. Journal of Medicinal Chemistry. 2007, May; 50(9): 2127-2136.
  1. 14.   Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: Implications for therapeutic discovery
  2. Stahl, A. M.; Ruthel, G.; Torres-Melendez, E.; Kenny, T. A.; Panchal, R. G.; Bavari, S.
  3. Journal of Biomolecular Screening. 2007, Apr; 12(3): 370-377.
  1. 15.   Hypoxia-inducible factor 1 inhibitors
  2. Melillo, G.
  3. Oxygen Biology and Hypoxia. 2007; 435 : 385-402.
  1. 16.   Identification of a new natural camptothecin analogue in targeted screening for HIF-1 alpha inhibitors
  2. Klausmeyer, P.; McCloud, T. G.; Melillo, G.; Scudiero, D. A.; Cardellina, J. H.; Shoemaker, R. H.
  3. Planta Medica. 2007, Jan; 73(1): 49-52.
  1. 17.   Development of therapeutics for chronic HCV infection
  2. Huang, Z.; Murray, M. G.; Secrist, J. A.
  3. Antiviral Research. 2006, Sep; 71(2-3): 351-362.
  1. 18.   Inhibiting hypoxia-inducible factor 1 for cancer therapy
  2. Melillo, G.
  3. Molecular Cancer Research. 2006, Sep; 4(9): 601-605.
  1. 19.   Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression
  2. Woldemichael, G. M.; Vasselli, J. R.; Gardella, R. S.; McKee, T. C.; Linehan, W. M.; McMahon, J. B.
  3. Journal of Biomolecular Screening. 2006, Sep; 11(6): 678-687.
  1. 20.   Mining the NCI antiviral compounds for HIV-1 integrase inhibitors
  2. Deng, J. X.; Kelley, J. A.; Barchi, J. J.; Sanchez, T.; Dayam, R.; Pommier, Y.; Neamati, N.
  3. Bioorganic & Medicinal Chemistry. 2006, JUN 1; 14(11): 3785-3792.
  1. 21.   Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
  2. Kong, D. H.; Park, E. J.; Stephen, A. G.; Calvani, M.; Cardellina, J. H.; Monks, A.; Fisher, R. J.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2005, OCT 1; 65(19): 9047-9055.
  1. 22.   The evolving field of biodefence: Therapeutic developments and diagnostics
  2. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S.
  3. Nature Reviews Drug Discovery. 2005 4(4): 281-297.
  1. 23.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huang, R.; Wallqvist, A.; Thanki, N.; Covell, D. G.
  3. Pharmacogenomics Journal. 2005 5(6): 381-399.
  1. 24.   Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization
  2. Nikolovska-Coleska, Z.; Wang, R. X.; Fang, X. L.; Pan, H. G.; Tomita, Y.; Li, P.; Roller, P. P.; Krajewski, K.; Saito, N. G.; Stuckey, J. A.; Wang, S. M.
  3. Analytical Biochemistry. 2004, SEP 15; 332(2): 261-273.
  1. 25.   Discovery and therapeutic potential of novel Bcl-2/Bcl-xL small-molecule inhibitors in human breast cancer
  2. Xu, L.; Wang, G.; Tang, N.; Nikolovska-Coleska, Z.; Wang, R.; Demchik, L.; Liu, M.; Zhang, M.; Roller, P.; Tomita, Y.; Yang, D.; Rae, J.; Lippman, M. E.; Wang, S.
  3. Breast Cancer Research and Treatment. 2004 88(Suppl. 1): S66, Abstract 1073-S66, Abstract 1073.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel